4576 — D.Western Therapeutics Institute Share Price
0.000.00%
Last trade - 00:00- ¥3bn
- ¥2bn
- ¥428m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.69 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.04% | ||
| Return on Equity | -51.79% | ||
| Operating Margin | -193.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 580.53 | 355.59 | 414.42 | 448.1 | 428.36 | n/a | n/a | 7.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
Directors
- Hiroyoshi Hidaka CHM (75)
- Yuichi Hidaka PRE (39)
- Tetsuya Kawakami OTH
- Eisaku Nakamura IND (56)
- Yoshiyuki Yamakawa IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 28th, 1999
- Public Since
- October 23rd, 2009
- No. of Shareholders
- 13,202
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 32,127,726
- Address
- 1-18-11, Nishiki, NAGOYA-SHI, 460-0003
- Web
- https://dwti.co.jp/
- Phone
- +81 522188785
- Auditors
- Grant Thornton Taiyo LLC
Upcoming Events for 4576
Dividend For 4576.T - 0.0000 JPY
Similar to 4576
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the D.Western Therapeutics Institute share price?
As of Today at 19:07 UTC, shares in D.Western Therapeutics Institute are trading at ¥107. This share price information is delayed by 15 minutes.
How has the D.Western Therapeutics Institute share price performed this year?
Shares in D.Western Therapeutics Institute last closed at ¥107 and the price had moved by -52.44% over the past 365 days. In terms of relative price strength the D.Western Therapeutics Institute share price has underperformed the Nikkei 225 Index by -64.21% over the past year.
What are the analyst and broker recommendations for D.Western Therapeutics Institute?
There is no consensus recommendation for this security.
What is the D.Western Therapeutics Institute dividend yield?
D.Western Therapeutics Institute does not currently pay a dividend.
Does D.Western Therapeutics Institute pay a dividend?
D.Western Therapeutics Institute does not currently pay a dividend.
When does D.Western Therapeutics Institute next pay dividends?
D.Western Therapeutics Institute does not currently pay a dividend.
How do I buy D.Western Therapeutics Institute shares?
To buy shares in D.Western Therapeutics Institute you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of D.Western Therapeutics Institute?
As of the previous close price of ¥107, shares in D.Western Therapeutics Institute had a market capitalisation of ¥3bn.
Where are D.Western Therapeutics Institute shares listed?
Here are the trading details for D.Western Therapeutics Institute:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4576
What kind of share is D.Western Therapeutics Institute?
Based on an overall assessment of its quality, value and momentum D.Western Therapeutics Institute is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a D.Western Therapeutics Institute share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the D.Western Therapeutics Institute share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like D.Western Therapeutics Institute. Over the past six months, its share price has underperformed the Nikkei 225 Index by -42.31%.
As of the last closing price of ¥107, shares in D.Western Therapeutics Institute were trading -32.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the D.Western Therapeutics Institute PE Ratio?
The D.Western Therapeutics Institute PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥107.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of D.Western Therapeutics Institute?
D.Western Therapeutics Institute's management team is headed by:
- Hiroyoshi Hidaka - CHM
- Yuichi Hidaka - PRE
- Tetsuya Kawakami - OTH
- Eisaku Nakamura - IND
- Yoshiyuki Yamakawa - IND